Correlation of enzyme-inducing anticonvulsant use with outcome of patients with glioblastoma.
Rosenow
F
F
Reif
P S
PS
Haag
A
A
Schmidt
K
K
Strik
H
H
D000927:Anticonvulsants / Q000494:pharmacology* / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000819:agonists / Q000627:therapeutic use; D001932:Brain Neoplasms / Q000188:drug therapy* / Q000401:mortality* / Q000473:pathology; D002986:Clinical Trials as Topic / Q000379:methods / Q000592:standards; D015897:Comorbidity; D003627:Data Interpretation, Statistical; D018450:Disease Progression; D004798:Enzymes / Q000187:drug effects / Q000378:metabolism; D004827:Epilepsy / Q000188:drug therapy / Q000453:epidemiology* / Q000503:physiopathology; D005909:Glioblastoma / Q000188:drug therapy* / Q000401:mortality* / Q000473:pathology; D006801:Humans; D015994:Incidence; D017063:Outcome Assessment, Health Care / Q000379:methods / Q000592:standards; D012720:Severity of Illness Index; D015996:Survival Rate; D016896:Treatment Outcome
D000927:Anticonvulsants; D000970:Antineoplastic Agents; D004798:Enzymes